Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report

BMC Infectious Diseases

Anna Fargnoli¹  Marco Motta¹  Monica Taverna¹  Daniela Di Mauro¹  Francesca Martini¹  Andrea D’Alessio¹  Marco Meazza Prina¹  Federico Bracchi¹  Giovanni Gobbin¹  Cristina Giussani¹ 

[1] Department of Internal Medicine and Onco-Haematology Policlinico S.Marco, GSD University and Research Hospital, Corso Europa 7, 24040, Zingonia, BG, Italy;

关键词: Hemophagocytic syndrome;    COVID-19;    Polyserositis;    Case report;   

DOI  :  10.1186/s12879-021-06532-7

来源: Springer

【 摘 要 】

BackgroundHemophagocytic syndrome (HPS) is a severe hyperinflammatory disease, whose diagnosis is based on the HLH-2004 criteria. In secondary forms of HLH (sHLH), the primary goal is treating the triggering factors such as COVID-19 (Coronavirus disease 2019). The link between the cytokine storm related to COVID-19 and development of sHLH has already been reported since the onset of pandemic, but little is known about clinical manifestations of HLH which develop after the patient’s recovery from mild symptomatic or asymptomatic Sars-CoV-2 infection.Case presentationWe describe the case of a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide and ruxolitinib.ConclusionsOur report suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection, even if the patient utterly recovered from the mildly symptomatic viral infection. In addition, we underline the treatment with low dose ruxolitinib plus etoposide as a potential choice for Sars-CoV-2 infection related HLH.

【 授权许可】

CC BY